0%

加衛苗® 9 Gardasil® 9 (Approved By Department of Health)
(9 in 1 HPV Vaccine)
Pharmaceutical Manufacturer - Merck Sharp & Dohme Corp.(US)

Registered age in Hong Kong
-Female:  9 year old onwards
-Male: 9 year old onwards

Against 9 types HPV
-High Risk Type: HPV 16, 18, New added( 31 ,33, 45, 52, 58 )
-Low Risk Type: HPV 6, 11

Vaccine Highlight
•    New added 5 types high risk HPV, which can provide 90% protection against cervical, vaginal, vulvar, and anal cancers and genital warts caused by 9 types of HPV.
•    Gardasil 9 helps protect against Genital Warts caused by HPV 6 & 11.

InjectionSchedule - 3 doses within 6 months (0, 2, 6)
Safety - Common side-effects include pain, swelling, redness, itchiness, bruise and fever
Booster - No instruction about the need of booster

加衛苗® Gardasil®(Approved By Department of Health)
(4 in 1 HPV Vaccine)
Pharmaceutical Manufacturer - Merck Sharp & Dohme Corp.(US)

Registered age in Hong Kong
-Female: 9 year old onwards
-Male: 9 year old onwards

Against 4 types HPV
-High Risk Type: HPV 16, 18
-Low Risk Type: HPV 6, 11

Characteristics
•    About 70% of cervical cancer is caused by HPV 16 and 18. Gardasil helps protect against Cervical Cancer caused by HPV 16 & 18 in female.
•    About 90% of Genital Warts are caused by HPV 6 and 11. Gardasil helps protect against Genital Warts caused by HPV 6 & 11 in female & male.

InjectionSchedule
-Aged 9- 13: 2 Dose within 6 months (0, 6)
-Aged 14 or above: 3 Dose within 6 months (0, 2, 6)
Safety - Common side-effects include pain, swelling, redness, itchiness, bruise and fever
Booster - No instruction about the need of booster

CervarixTM (Approved By Department of Health)
(2 in 1 HPV Vaccine)
Pharmaceutical Manufacturer – GlaxoSmithKline

Registered age in Hong Kong
-Female: 9 years old onwards

Against 2 types HPV
-High Risk Type: HPV 16, 18

Characteristics
•    9.4 years sustained antibody levels against HPV 16 & 18, provide higher level of protection against Cervical Cancer. * Up to 9.4 years post-vaccination, the antibody levels of HPV 16 & 18 were at least 14 & 10-fold above natural infection levels respectively.
•    93% overall efficacy against CIN3+ irrespective of HPV Type.

InjectionSchedule
-Aged 9- 14: 2 Dose within 6 months (0, 6)
-Aged 15 or above: 3 Dose within 6 months (0, 1, 6)
Safety - Major side-effects include swelling, pain, redness and fever
Booster - No instruction about the need of booster